Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Prostate cancer detection with PET CT and PET MRI is comparable.

2.

Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy

3.

AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns

4.

In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.

5.

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot